Shopping Cart
- Remove All
- Your shopping cart is currently empty
Vorsetuzumab mafodotin, a humanized anti-CD70 monoclonal antibody, conjugates with monomethyl auristatin F (MMAF) through Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. This affinity allows targeting of various solid tumors and cancers such as renal cell carcinoma, pancreatic, ovarian, and lung cancers, alongside multiple myeloma and several forms of non-Hodgkin lymphoma, all of which express CD70.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Vorsetuzumab mafodotin, a humanized anti-CD70 monoclonal antibody, conjugates with monomethyl auristatin F (MMAF) through Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. This affinity allows targeting of various solid tumors and cancers such as renal cell carcinoma, pancreatic, ovarian, and lung cancers, alongside multiple myeloma and several forms of non-Hodgkin lymphoma, all of which express CD70. |
Alias | SGN-75, h1F6-mcMMAF, Anti-TNFSF7 / CD27L / CD70 Reference Antibody |
Molecular Weight | 146.1 kDa |
Storage | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.